Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Final Patient Completes Prosonix’ Phase 2 Clinical Study with PSX1002

Published: Monday, August 19, 2013
Last Updated: Monday, August 19, 2013
Bookmark and Share
PSX1002 is a novel, orally inhaled, drug-only, pMDI suspension formulation of glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA).

Prosonix has completed all patient dosing sessions and follow-up procedures in its Phase 2 clinical study with PSX1002.

PSX1002 is a novel, drug-only suspension formulation of the long-acting muscarinic antagonist (LAMA), glycopyrronium bromide (GB), which is in development as a potential ‘best-in-class’ orally inhaled monotherapy for chronic obstructive pulmonary disease (COPD).

PSX1002 was designed using Prosonix’ proprietary particle engineering technology platform. This platform has enabled the Company to create and undertake the clinical study with a simple suspension formulation of GB for delivery via a pressurized metered dose inhaler (pMDI) that does not require or contain any other extraneous carriers or functional excipients.

The Phase 2 single-dose study is investigating the effect of PSX1002 on lung function and the safety of a range of doses in patients with moderate to severe COPD.

The study has recruited and treated 37 COPD patients at the Medicines Evaluation Unit in Manchester, UK, where the study was conducted under the supervision of Professor Dave Singh.

Further details are below. Top-line results of this study are expected to be announced in Q1 2014.

David Hipkiss, CEO of Prosonix, said: “Our rapid progress in completing patient recruitment and all clinical procedures for this Phase 2 trial with PSX1002, on time and to plan, is a significant achievement for the Company. We believe that our novel formulation of glycopyrronium bromide, which is underpinned by our “Respiratory Medicine by Design” philosophy and designed, developed and enabled using our unique particle engineering technology, could deliver considerable clinical benefits to COPD patients. We look forward to reporting top-line results in the near future.”

Mr Hipkiss added: “In addition to the excellent progress with PSX1002, we continue to advance our development pipeline of particle-engineered mono and combination respiratory medicines, with the first filing of our lead product PSX1001 in the European Union as a directly substitutable generic inhaled corticosteroid (ICS) for asthma and COPD expected in mid-2014.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Prosonix Confirms the Potential of its Multi-component Particle™ Technology
Successful completion of biomedical catalyst programme.
Thursday, September 11, 2014
Prosonix Reports Positive Top-line Results from its Phase 2 Clinical Study with PSX1002
First clinical data from PSX1002, a novel, orally inhaled, drug-only, pMDI suspension formulation of glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA).
Friday, January 31, 2014
Prosonix Initiates Phase 2 Clinical Study with PSX1002 in COPD Patients
First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix’ particle engineering platform.
Thursday, May 23, 2013
Prosonix Appoints Cécile Miles as Chief Business Officer
Appointment significantly strengthens corporate and commercial development experience in the generics and speciality pharmaceutical markets.
Tuesday, February 12, 2013
Prosonix Secures £11.4M Series B Financing
Revolutionizing respiratory medicine.
Wednesday, August 24, 2011
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos